NTRA

$378.738.59%-35.57

Nachbörslich: 375.00-3.73 -0.98%

Natera Inc (NTRA)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$414.30

Offen:

$418.41

24-Stunden-Volumen:

2,359,300

Relatives Volumen:

1.47

Marktkapitalisierung:

$54.59B

Einnahmen:

$2.50B

Nettoeinkommen (Verlust:

-$226.32M

KGV:

EPS:

-$1.64

Netto-Cashflow:

$71.51M

1W Leistung:

-6.46%

1M Leistung:

-7.71%

6M Leistung:

+82.71%

1Y Leistung:

+90.38%

1-Tages-Spanne:

$376.38$418.41

1-Wochen-Bereich:

$376.38$436.19

52-Wochen-Spanne:

$181.00$437.41

Natera Inc Aktie (NTRA) Unternehmensprofil

Firmenname

Natera Inc

Sektor

Healthcare

Branche

Diagnostics & Research

Telefon

650-249-9090

Adresse

13011 MCCALLEN PASS, AUSTIN, CA, USA

Mitarbeiter

6,140

@nateragenetics

Nächster Verdiensttermin

2026-11-05

Neueste SEC-Einreichungen

SEC

NTRA-Diskussionen auf X

NTRA vs. TMO, DHR, IDXX, A vergleichen

Aktien	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NTRA Natera Inc	$54.59B	$2.71B	-$192.35M	$84.20M	-$1.64
TMO Thermo Fisher Scientific Inc	$252.41B	$47.35B	$7.07B	$7.60B	$18.19
DHR Danaher Corp	$160.33B	$25.61B	$4.33B	$5.73B	$5.17
IDXX Idexx Laboratories Inc	$52.93B	$4.66B	$1.18B	$1.30B	$13.59
A Agilent Technologies Inc	$48.50B	$7.37B	$1.44B	$1.27B	$4.98

Natera Inc Aktie (NTRA) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-10-23	Eingeleitet	Roth Capital	Buy
2026-09-09	Resumed	UBS	Buy
2026-09-08	Eingeleitet	Rothschild & Co Redburn	Buy
2026-06-26	Resumed	Bernstein	Outperform
2026-06-12	Resumed	RBC Capital Mkts	Outperform
2026-06-02	Resumed	Wolfe Research	Outperform
2026-04-14	Eingeleitet	William Blair	Outperform
2026-01-07	Eingeleitet	Citigroup	Buy
2025-12-02	Resumed	Morgan Stanley	Overweight
2025-10-27	Hochstufung	BNP Paribas Exane	Underperform → Neutral
2025-09-22	Resumed	Wells Fargo	Equal Weight
2025-03-13	Eingeleitet	RBC Capital Mkts	Outperform
2025-01-23	Eingeleitet	Barclays	Overweight
2024-06-03	Resumed	Jefferies	Buy
2024-04-08	Resumed	Craig Hallum	Buy
2024-02-20	Herabstufung	Raymond James	Strong Buy → Outperform
2023-12-29	Bestätigt	BTIG Research	Buy
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-11-13	Hochstufung	Raymond James	Outperform → Strong Buy
2023-09-28	Eingeleitet	Bernstein	Mkt Perform
2023-07-05	Resumed	JP Morgan	Overweight
2023-05-05	Eingeleitet	UBS	Buy
2023-01-18	Hochstufung	Raymond James	Mkt Perform → Outperform
2022-08-25	Eingeleitet	Credit Suisse	Outperform
2022-04-25	Eingeleitet	Stephens	Overweight
2022-03-08	Eingeleitet	Goldman	Buy
2022-01-06	Resumed	Piper Sandler	Overweight
2021-10-15	Resumed	Cowen	Outperform
2021-06-15	Eingeleitet	Raymond James	Mkt Perform
2021-05-25	Eingeleitet	Wells Fargo	Overweight
2021-01-28	Eingeleitet	Truist	Buy
2020-10-08	Eingeleitet	BTIG Research	Buy
2020-09-28	Eingeleitet	Morgan Stanley	Overweight
2020-09-17	Eingeleitet	SVB Leerink	Outperform
2020-06-10	Resumed	Piper Sandler	Overweight
2020-05-07	Hochstufung	JP Morgan	Neutral → Overweight
2018-10-05	Eingeleitet	JP Morgan	Neutral
2018-07-05	Bestätigt	Piper Jaffray	Overweight
2017-08-07	Bestätigt	Morgan Stanley	Overweight
2016-11-10	Bestätigt	The Benchmark Company	Buy
2016-05-23	Bestätigt	The Benchmark Company	Buy
2016-05-11	Bestätigt	The Benchmark Company	Buy
2016-04-19	Eingeleitet	The Benchmark Company	Buy
2015-09-28	Hochstufung	Wedbush	Neutral → Outperform
2015-08-14	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2015-08-04	Eingeleitet	Robert W. Baird	Outperform
2015-07-27	Eingeleitet	Morgan Stanley	Equal-Weight
2015-07-27	Eingeleitet	Piper Jaffray	Overweight
2015-07-27	Eingeleitet	Wedbush	Neutral

Finanzdaten der Natera Inc-Aktie (NTRA)

Zeitraum	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	2,306.11	1,696.91	1,082.57	820.22	625.49
Research and development USD (M)	624.11	404.14	320.68	316.42	264.21
Operating expenses USD (M)	2,616.02	1,919.21	1,528.82	1,361.26	1,093.66
Operating income USD (M)	-309.91	-222.29	-446.25	-541.04	-468.17
Income before tax USD (M)	-268.09	-189.73	-434.53	-546.82	-471.10
Income tax expense USD (M)	-59.93	0.70	0.27	0.98	0.62
Net income USD (M)	-208.16	-190.43	-434.80	-547.80	-471.72
Basic EPS USD/shares	-1.52	-1.53	-3.78	-5.57	-5.21
Diluted EPS USD/shares	-1.52	-1.53	-3.78	-5.57	-5.21
Basic weighted shares shares (M)	136.72	124.72	115.00	98.41	90.56
Diluted weighted shares shares (M)	136.72	124.72	115.00	98.41	90.56
Selling, general and administrative USD (M)	1,177.26	841.31	618.31	588.59	511.03

Natera Inc-Aktie (NTRA) Insiderhandel

JONATHAN SHEENANov 02 '26
DIRECTOR
Transaktion
Proposed Sale
Kosten
$414.30
#Aktien
108
Wert ($)
44,744
#Aktien Gesamt
0
STEVEN L CHAPMANNov 02 '26
Officer
Transaktion
Proposed Sale
Kosten
$415.64
#Aktien
2,866
Wert ($)
1,191,224
#Aktien Gesamt
0
SOLOMON MOSHKEVICHNov 02 '26
OFFICER
Transaktion
Proposed Sale
Kosten
$414.30
#Aktien
405
Wert ($)
167,792
#Aktien Gesamt
0
MICHAEL BROPHYNov 02 '26
OFFICER
Transaktion
Proposed Sale
Kosten
$414.30
#Aktien
313
Wert ($)
129,676
#Aktien Gesamt
0
SOLOMON MOSHKEVICHNov 02 '26
Officer
Transaktion
Proposed Sale
Kosten
$411.13
#Aktien
3,000
Wert ($)
1,233,380
#Aktien Gesamt
0
JOHN FESKONov 02 '26
OFFICER
Transaktion
Proposed Sale
Kosten
$414.30
#Aktien
291
Wert ($)
120,561
#Aktien Gesamt
0
STEVEN CHAPMANNov 02 '26
OFFICER
Transaktion
Proposed Sale
Kosten
$414.30
#Aktien
903
Wert ($)
374,113
#Aktien Gesamt
0
DANIEL RABINOWITZNov 02 '26
OFFICER
Transaktion
Proposed Sale
Kosten
$414.30
#Aktien
330
Wert ($)
136,719
#Aktien Gesamt
0
MATTHEW RABINOWITZNov 02 '26
DIRECTOR
Transaktion
Proposed Sale
Kosten
$414.30
#Aktien
722
Wert ($)
299,125
#Aktien Gesamt
0
Brophy Michael BurkesOct 30 '26
CHIEF FINANCIAL OFFICER
Transaktion
Sale
Kosten
$425.55
#Aktien
1,906
Wert ($)
811,098
#Aktien Gesamt
46,574

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
JONATHAN SHEENA	DIRECTOR	Nov 02 '26	Proposed Sale	$414.30	108	44,744	0
STEVEN L CHAPMAN	Officer	Nov 02 '26	Proposed Sale	$415.64	2,866	1,191,224	0
SOLOMON MOSHKEVICH	OFFICER	Nov 02 '26	Proposed Sale	$414.30	405	167,792	0
MICHAEL BROPHY	OFFICER	Nov 02 '26	Proposed Sale	$414.30	313	129,676	0
SOLOMON MOSHKEVICH	Officer	Nov 02 '26	Proposed Sale	$411.13	3,000	1,233,380	0
JOHN FESKO	OFFICER	Nov 02 '26	Proposed Sale	$414.30	291	120,561	0
STEVEN CHAPMAN	OFFICER	Nov 02 '26	Proposed Sale	$414.30	903	374,113	0
DANIEL RABINOWITZ	OFFICER	Nov 02 '26	Proposed Sale	$414.30	330	136,719	0
MATTHEW RABINOWITZ	DIRECTOR	Nov 02 '26	Proposed Sale	$414.30	722	299,125	0
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 30 '26	Sale	$425.55	1,906	811,098	46,574

Natera Inc Aktie (NTRA) Neueste Nachrichten

Oct 30, 2026

Natera CFO Michael Brophy sells $1.31 million in common stock By Investing.com - Investing.com Canada

Oct 30, 2026

Oct 29, 2026

Natera president John Fesko sells $699,939 in common stock - Investing.com

Oct 29, 2026

Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 27 October - Investing.com UK

Oct 29, 2026

To cover stock-vesting taxes, Natera (NTRA) president sells 2,172 shares. - Stock Titan

Oct 29, 2026

To cover vesting taxes, Natera (NTRA) CFO sells 781 shares and another 1,198. - Stock Titan

Oct 29, 2026

CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates - Zacks Investment Research

Oct 29, 2026

Oct 28, 2026

An officer proposes selling 1,185 Natera (NTRA) shares worth $487K after stock awards vested. - Stock Titan

Oct 28, 2026

An officer proposes selling 1,222 Natera (NTRA) shares acquired through stock-grant vesting. - Stock Titan

Oct 28, 2026

NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results? - Zacks Investment Research

Oct 28, 2026

Oct 27, 2026

Natera Director Matthew Rabinowitz Files to Sell 1,697 RSU Shares Worth $687K - Kalkine Media

Oct 27, 2026

Natera Officer Daniel Rabinowitz Announces Plan to Sell 873 Shares Following RSU Vesting - Kalkine Media

Oct 27, 2026

Natera Officer John Fesko Announces Intent to Sell 771 Shares Valued at $312K - Kalkine Media

Oct 27, 2026

After stock-award vesting, Natera (NTRA) officer John Fesko proposes a $312K sale of 771 shares. - Stock Titan

Oct 27, 2026

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool

Oct 27, 2026

Oct 26, 2026

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? - Zacks Investment Research

Oct 26, 2026

Oct 25, 2026

Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree. - The Motley Fool

Oct 25, 2026

Oct 23, 2026

Natera Co-Founder Sheena Jonathan Disposes of 3,150 Shares Under Rule 10b5-1 Plan on October 21, 2026 - Kalkine Media

Oct 23, 2026

Oct 22, 2026

Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool

Oct 22, 2026

Oct 21, 2026

Natera Director Sheena Jonathan Files to Sell 9,450 Shares Valued at $3.88 Million - Kalkine Media

Oct 21, 2026

After a $7.01M September sale, a Natera (NTRA) director proposes another share sale. - Stock Titan

Oct 21, 2026

Natera Partners With TransCode to Advance Colorectal Cancer Trial - Zacks Investment Research

Oct 21, 2026

Oct 20, 2026

Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com Australia

Oct 20, 2026

Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com Nigeria

Oct 20, 2026

Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com India

Oct 20, 2026

Oct 19, 2026

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)? - Zacks Investment Research

Oct 19, 2026

Oct 16, 2026

Form 4 Natera Inc: Matthew Rabinowitz (Director, EXECUTIVE CHAIRMAN) For: 15 October - Investing.com Nigeria

Oct 16, 2026

Form 4 Natera Inc: Matthew Rabinowitz (Director, EXECUTIVE CHAIRMAN) For: 15 October - Investing.com Canada

Oct 16, 2026

Under a preset plan, Natera (NTRA)'s chairman sells 50,000 shares; he also exercises options. - Stock Titan

Oct 16, 2026

Oct 15, 2026

Natera Director Matthew Rabinowitz Files Form 144 to Sell 50,000 Shares Valued at $19.7M - Kalkine Media

Oct 15, 2026

$19.7M in Natera (NTRA) shares is proposed for sale following three September sales. - Stock Titan

Oct 15, 2026

Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million - GlobeNewswire Inc.

Oct 15, 2026

Oct 14, 2026

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Zacks Investment Research

Oct 14, 2026

Oct 12, 2026

Tempus AI Expands Strategic Collaborations to Drive Future Growth - Zacks Investment Research

Oct 12, 2026

Oct 09, 2026

Matthew Rabinowitz Donates 6,000 Natera Shares to Charity on October 7, 2026 - Kalkine Media

Oct 09, 2026

Oct 03, 2026

Natera CEO Steven Chapman sells $526k in common stock By Investing.com - Investing.com UK

Oct 03, 2026

Natera CEO Steven Chapman sells $526k in common stock - Investing.com

Oct 03, 2026

Oct 02, 2026

Natera (NTRA) clinical diagnostics president sells 3,000 shares under a trading plan. - Stock Titan

Oct 02, 2026

Oct 01, 2026

Morgan Stanley Smith Barney is broker for a proposed 1,273-share sale at Natera (NTRA). - Stock Titan

Oct 01, 2026

After five sales in three months, a Natera (NTRA) officer proposes another stock sale. - Stock Titan

Oct 01, 2026

Sep 26, 2026

Under a preset plan, two trusts sold 18,064 Natera (NTRA) shares in 12 transactions. - Stock Titan

Sep 25, 2026

Natera director Sheena’s trusts dispose of $7.0m in NTRA stock - Investing.com

Sep 25, 2026

Sep 23, 2026

Natera Director Sheena Jonathan to Offload 21,064 Shares Worth $8.16M, Form 144 Filed - Kalkine Media

Sep 23, 2026

Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx - Zacks Investment Research

Sep 23, 2026

$8.2M stock sale planned at Natera (NASDAQ: NTRA) - Stock Titan

Sep 23, 2026

Sep 17, 2026

Natera (NASDAQ: NTRA) co-founder sells 9,150 shares under 10b5-1 plan - Stock Titan

Sep 17, 2026

Sep 16, 2026

Natera (NASDAQ: NTRA) chair unloads stock in preset plan - Stock Titan

Sep 16, 2026

Sep 15, 2026

Trust tied to Natera (NASDAQ: NTRA) eyes new stock sale after multimillion-dollar trades - Stock Titan

Sep 15, 2026

Ähnlich wie NTRA

Natera Inc (NTRA)

Natera Inc Aktie (NTRA) Unternehmensprofil

NTRA vs. TMO, DHR, IDXX, A vergleichen

Natera Inc Aktie (NTRA) Hochstufungen & Herabstufungen

Finanzdaten der Natera Inc-Aktie (NTRA)

Natera Inc-Aktie (NTRA) Insiderhandel

Natera Inc Aktie (NTRA) Neueste Nachrichten

Natera CFO Michael Brophy sells $1.31 million in common stock By Investing.com - Investing.com Canada

Natera president John Fesko sells $699,939 in common stock - Investing.com

Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 27 October - Investing.com UK

To cover stock-vesting taxes, Natera (NTRA) president sells 2,172 shares. - Stock Titan

To cover vesting taxes, Natera (NTRA) CFO sells 781 shares and another 1,198. - Stock Titan

CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates - Zacks Investment Research

An officer proposes selling 1,185 Natera (NTRA) shares worth $487K after stock awards vested. - Stock Titan

An officer proposes selling 1,222 Natera (NTRA) shares acquired through stock-grant vesting. - Stock Titan

NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results? - Zacks Investment Research

Natera Director Matthew Rabinowitz Files to Sell 1,697 RSU Shares Worth $687K - Kalkine Media

Natera Officer Daniel Rabinowitz Announces Plan to Sell 873 Shares Following RSU Vesting - Kalkine Media

Natera Officer John Fesko Announces Intent to Sell 771 Shares Valued at $312K - Kalkine Media

After stock-award vesting, Natera (NTRA) officer John Fesko proposes a $312K sale of 771 shares. - Stock Titan

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? - Zacks Investment Research

Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree. - The Motley Fool

Natera Co-Founder Sheena Jonathan Disposes of 3,150 Shares Under Rule 10b5-1 Plan on October 21, 2026 - Kalkine Media

Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool

Natera Director Sheena Jonathan Files to Sell 9,450 Shares Valued at $3.88 Million - Kalkine Media

After a $7.01M September sale, a Natera (NTRA) director proposes another share sale. - Stock Titan

Natera Partners With TransCode to Advance Colorectal Cancer Trial - Zacks Investment Research

Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com Australia

Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com Nigeria

Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com India

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)? - Zacks Investment Research

Form 4 Natera Inc: Matthew Rabinowitz (Director, EXECUTIVE CHAIRMAN) For: 15 October - Investing.com Nigeria

Form 4 Natera Inc: Matthew Rabinowitz (Director, EXECUTIVE CHAIRMAN) For: 15 October - Investing.com Canada

Under a preset plan, Natera (NTRA)'s chairman sells 50,000 shares; he also exercises options. - Stock Titan

Natera Director Matthew Rabinowitz Files Form 144 to Sell 50,000 Shares Valued at $19.7M - Kalkine Media

$19.7M in Natera (NTRA) shares is proposed for sale following three September sales. - Stock Titan

Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million - GlobeNewswire Inc.

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Zacks Investment Research

Tempus AI Expands Strategic Collaborations to Drive Future Growth - Zacks Investment Research

Matthew Rabinowitz Donates 6,000 Natera Shares to Charity on October 7, 2026 - Kalkine Media

Natera CEO Steven Chapman sells $526k in common stock By Investing.com - Investing.com UK

Natera CEO Steven Chapman sells $526k in common stock - Investing.com

Natera (NTRA) clinical diagnostics president sells 3,000 shares under a trading plan. - Stock Titan

Morgan Stanley Smith Barney is broker for a proposed 1,273-share sale at Natera (NTRA). - Stock Titan

After five sales in three months, a Natera (NTRA) officer proposes another stock sale. - Stock Titan

Form 4 Natera Inc For: 25 September By Investing.com - Investing.com UK

Form 4 Natera Inc For: 25 September By Investing.com - Investing.com Australia

Form 4 Natera Inc For: 25 September By Investing.com - Investing.com Nigeria

Under a preset plan, two trusts sold 18,064 Natera (NTRA) shares in 12 transactions. - Stock Titan

Natera director Sheena’s trusts dispose of $7.0m in NTRA stock - Investing.com

Natera Director Sheena Jonathan to Offload 21,064 Shares Worth $8.16M, Form 144 Filed - Kalkine Media

Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx - Zacks Investment Research

$8.2M stock sale planned at Natera (NASDAQ: NTRA) - Stock Titan

Natera (NASDAQ: NTRA) co-founder sells 9,150 shares under 10b5-1 plan - Stock Titan

Natera (NASDAQ: NTRA) chair unloads stock in preset plan - Stock Titan

Trust tied to Natera (NASDAQ: NTRA) eyes new stock sale after multimillion-dollar trades - Stock Titan

Ähnlich wie NTRA